Evaluation of respiratory syncytial virus (RSV) vaccine eligibility in an outpatient adult infectious diseases clinic. [PDF]
Liu A, Stack C, Mahoney MV.
europepmc +1 more source
Antiviral activity of the non-steroidal anti-inflammatory drug indomethacin against respiratory syncytial virus. [PDF]
Tramontozzi C +4 more
europepmc +1 more source
Phylodynamics and molecular epidemiology of the respiratory syncytial virus fusion protein in China. [PDF]
Amjad MN +14 more
europepmc +1 more source
Optimizing the sensitivity of detection of respiratory syncytial virus infections in longitudinal studies using the combination of weekly sample testing and biannual serology. [PDF]
Conrey SC +12 more
europepmc +1 more source
Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. [PDF]
Kura K +7 more
europepmc +1 more source
Factors Affecting Maternal Respiratory Syncytial Virus Vaccination and the Impact on Infant Hospitalization During the 2023-2024 Season in Dallas, Texas. [PDF]
Bailey NA, Most ZM.
europepmc +1 more source
Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative Children [PDF]
Abstract Background This United States-based study compared 2 candidate vaccines: RSV/ΔNS2/Δ1313/I1314L, attenuated by NS2 gene-deletion and temperature-sensitivity mutation in the polymerase gene; and RSV/276, attenuated by M2-2 deletion. Methods
Coleen K Cunningham +2 more
exaly +4 more sources
Related searches:
Predicting the RSV Surge: Pediatric RSV Patterns of the COVID Pandemic
Pediatric Infectious Disease Journal, 2023Historically, respiratory syncytial virus (RSV) infection trends have been predictable. The COVID-19 pandemic and associated precautions impacted RSV disease patterns. RSV infection trends during the first year of the COVID-19 pandemic may have predicted the 2022 surge in pediatric RSV infections.
Sidney Zven +5 more
openaire +2 more sources

